Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Acquired Immunodeficiency Syndrome
Interventions
DRUG

lopinavir/ritonavir

Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.

Trial Locations (1)

SW10 9TH

St Stephen's Centre, Chelsea and Westminster Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Kirby Institute

OTHER_GOV

NCT00985543 - Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses. | Biotech Hunter | Biotech Hunter